Mordecai Klein
Cardiovascular Disease · Plano, TXNPI 1881629541
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,902 of the $2,296 with a category attached, or 82.9%. Abbott accounts for 71.8% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $671 and has fallen 97.8% since, to $15 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in TX, where the typical reported total is $3,258.
Across 68 payments — averaging $33.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$202
- Abiomed$146
- Philips North America LLC$95
- Amgen$52
- Boston Scientific$32
- plus $121 from 6 others
Across 718 payments — averaging $519.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$194K
- Eli Lilly$161K
- Pfizer$18K
What the payments were for
- Food & beverage$1,90283%
- Education$39417%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 44 | $1,649 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $202 |
| Abiomed | 1 | $146 |
| Philips North America LLC | 2 | $95 |
| Amgen | 4 | $52 |
| Boston Scientific | 1 | $32 |
| Merck | 2 | $32 |
| Irhythm Technologies, Inc. | 1 | $22 |
| Itamar Medical Inc | 1 | $20 |
| Pfizer | 1 | $20 |
| Medtronic | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Confirm Rx$538
- XIENCE SKYPOINT$154
- Impella$146
How this compares
$2,296 in reported general payments places this provider in the 40th percentile of 1,515 cardiovascular disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $12,305 |
| Metoprolol Succinate | 26 | $444 |
| Atorvastatin Calcium | 27 | $225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $20 | $12,30511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Plano
- Sahil BakshiPlano$167K
- David RawitscherPlano$122K
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.